The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients

Phase 3UnknownNCT03991910

Indonesia University66 enrolled

Overview

Objective propose: to investigate the effect of Ramipril in suppressing ST2 (suppression of tumorigenicity 2) in the cardiac mitral valve in patients with Rheumatic Heart Disease. We hypothesized that we hypothesized that ramipril will improve rheumatic mitral valve fibrosis through the downregulation of ST2.

The efficacy of secondary prevention is limited in the prevention of RHD progression. For this reason, new strategies and therapies are needed to prevent the progression of RHD. Neutralizing inflammatory cytokines or antagonizing their receptor function has been considered as a useful therapeutic strategy to treat autoimmune diseases. In this respect, new therapies targeting ST 2 and their receptors as studied in some autoimmune diseases may promise a new approach for patients with RHD. Angiotensin II induces the upregulation of Transforming growth factor β (TGF-β) and latter the binding of IL-33 to sST2 and not to the natural ligand (ST2L). The binding of IL-33 to sST2 will cause fibrogenesis even more. Thus, ACEI is hypothesized to attenuate this vicious cycle through the inhibition of Angiotensin II and consequently increase Bradykinin that furtherly inhibits fibrosis through the negative regulation of angiotensin II activity in Mitogen Activator Protein Kinase (MAPK) pathways through the suppression of the Ca2+ response and the Na+ transportACE inhibitor were agents with anti-fibrosis effects. The investigators keen to investigate the effect of Ramipril in suppressing ST2 expression as biomarkers of fibrosis in cardiac mitral valve in patients with Rheumatic Heart Disease in the National Cardiac Center Harapan Kita hospital Jakarta Indonesia. This study was designed as a randomized clinical trial. Patients with mitral stenosis valvular dysfunction due to rheumatic process planned for cardiac valve replacement surgery were given Ramipril or placebo for a minimum of 12 weeks (3 months). ST2 expression will be analyzed as the fibrosis biomarker in the mitral valve. This study will be conducted in the Department of Cardiology and Vascular Medicine, University Indonesia, National Cardiac Center Harapan Kita Hospital, Jakarta, Indonesia from June 2019

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Conditions

Rheumatic Heart Disease Mitral Stenosis Rheumatic Mitral Stenosis Fibrosis; Heart ACE Inhibitor

Interventions

PlacebosDRUG

the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.

Ramipril 5Mg Oral CapsuleDRUG

the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with mitral valve stenosis or a combination * aged more than 18 years * undergo cardiac valve replacement operation with or without a tricuspid valve repair, * patients with systolic blood pressure (SBP) ≥ 100 mmHg and diastolic blood pressure (DBP) ≥ 60 mmHg * passed in medication phase without side effect minimum 4 weeks until operation schedule Exclusion Criteria: 1. Patients with congenital heart disease 2. patients with non-mitral valve surgery 3. patients with coronary artery bypass surgery 4. patients who refuse to join this study. 5. adults aged over 65 years or older 6. pregnant women 7. patients with autoimmune disease. 8. Patients with persistent hypotension (systolic blood pressure (BP) \< 100 mm Hg) 9. severe aortic stenosis (aortic valve orifice \< 0.75 cm2 ) 10. chronic renal dysfunction with serum creatinine \> 2.5 mg/ dL, 11. known ACEI intolerance.

Locations (1)

Ade Meidian Ambari

Jakarta, DKI Jakarta, Indonesia

RECRUITING

Outcomes

Primary Outcomes

ST2 expression in mitral valve tissue and papillary muscle

expression of ST2 in mitral valve tissue, using immunohistochemistry method

Time frame: a year

Secondary Outcomes

ST2 Plasma concentration

plasma level of ST2 measured by ELISA

Time frame: a year

NT-proBNP concentration (pg/ml)

concentration of NT-proBNP, plasma markers for cardiac dysfunction.

Time frame: a year

NYHA class

related symptoms will be graded in class I to IV according to NYHA.

Time frame: a year

cardiovascular mortality

Study participants will be followed up until 1 year after the surgery for any mortality that is caused by progression of the cardiac disease

Time frame: 1 year

All-cause mortality

Study participants will be followed up until 1 year after the surgery for mortality of any cause.

Time frame: 1 year

End diastolic dimension

The diameter across a ventricle at the end of diastole, if not else specified then usually referring to the transverse (left-to-right) internal (luminal) distance, excluding thickness of walls, although it can also be measured as the external distance.

Time frame: 1 year

End systolic dimension

The diameter across a ventricle at the end of systole, if not else specified then usually referring to the transverse (left-to-right) internal (luminal) distance, excluding thickness of walls, although it can also be measured as the external distance.

Central Contacts

Ade Meidian Ambari, MD, FIHA

CONTACT

021-5684085 dr_ade_meidian@yahoo.co.id

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.